Understanding chromosome aberrations through cytogenomic analysis is an integral part of current genomic medicine, playing a role in research into both constitutional disorders and cancer.
At Illumina, we collaborate with industry experts, thought leaders, and customers to develop solutions to meet your evolving research needs. Now you can perform sequencing and high-quality cytogenomic array scanning all on a single platform.
Next-generation sequencing (NGS) offers detection capabilities that complement arrays. By providing a base-by-base view of the genome, NGS can identify single nucleotide variants (SNV), small structural changes, and balanced translocations, providing researchers with a genome-wide view of variation.
NGS can be used to confirm copy number variants detected by arrays. Together, the 2 methods are ideal for cytogenomic studies across a spectrum of reproductive and genetic health applications. Now you can perform both NGS and array scanning on a single system, the NextSeq 550 System.View NextSeq 550 System
Traditional molecular cytogenomic methods for assessing chromosomal abnormalities, including FISH and karyotyping, enable genome visualization, but often at a low resolution. As a result, data from these methods can often be inconsistent.
Cytogenomic microarrays offer a simpler, more reliable method for assessing chromosomal aberrations at a higher resolution. Illumina offers industry-leading chromosomal microarrays designed to detect chromosome aberrations and provide accurate, reliable cytogenomic data with: